Just-Evotec Biologics Secures Gates Foundation Grant for AI-Driven Monoclonal Antibody Optimization to Expand Global Access
核心洞察
Just-Evotec Biologics (搜索) received a new Gates Foundation (搜索) grant to utilize its J.MD molecular design suite for optimizing monoclonal antibodies (搜索) and other biologic modalities to improve global access to biotherapeutics (搜索).
The investment will enable ten new J.MD projects over three years, focusing on molecular optimization including improved pharmacokinetics, immunogenicity, and stability to reduce costs and expand accessibility in low- and middle-income countries.
This grant extends Just-Evotec Biologics (搜索)' collaboration with the Gates Foundation (搜索) that began in 2014 and has delivered multiple cGMP manufacturing campaigns for RSV (搜索), malaria (搜索), and HIV (搜索) monoclonal antibodies (搜索).
Just-Evotec Biologics (搜索), the Seattle-based subsidiary of Evotec SE, has secured a new grant from the Gates Foundation (搜索) to advance global access to biotherapeutics (搜索) through artificial intelligence-driven optimization of monoclonal antibodies (搜索). The investment will leverage the company's J.MD molecular design suite of computational technologies to reduce development costs and improve accessibility of life-saving treatments in low- and middle-income countries.
Expanding AI-Driven Biologics Development
The grant will enable ten new J.MD projects over the next three years, encompassing molecular optimization across multiple parameters including improved titer, pharmacokinetics, immunogenicity, and stability. This investment continues the Gates Foundation (搜索)'s support for selected grantees working to improve the developability and reduce the cost of goods of monoclonal antibodies (搜索) to make them more affordable and accessible for preventing infectious diseases in underserved regions.
Under the grant terms, Just-Evotec Biologics (搜索) will utilize its J.MD Molecular Design service, a key component of its J.DESIGN platform that integrates advanced computational tools and high-throughput methodologies to streamline the biologics development process. By optimizing molecular design from the earliest stages, J.MD ensures manufacturability, stability, and efficacy—critical factors for reducing costs and enabling expansion of global access to these therapies while limiting liabilities such as immunogenicity and instability.
Building on Established Partnership
This new grant extends Just-Evotec Biologics (搜索)' commitment to global health initiatives that began in 2014. Since then, the company has delivered multiple cGMP manufacturing campaigns for monoclonal antibodies (搜索) targeting RSV (搜索), malaria (搜索), and HIV (搜索). The new investment will span the development of biotherapeutics (搜索) targeting multiple global health disease indications of concern.
"We are thrilled to receive this new grant from the Gates Foundation (搜索) which will strengthen our commitment to reducing the cost of biologics development to expand global access," said Dr. Linda Zuckerman, EVP and Global Head of Just-Evotec Biologics (搜索). "By leveraging our J.DESIGN platform and innovative molecular design tools, we look forward to supporting the foundation in driving impactful solutions across multiple disease areas and continuing to deliver therapies where they are needed most."
Strategic Impact on Global Health
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the broader implications of the partnership: "We are proud to continue our collaboration with the foundation through this new grant which enables us to harness Just-Evotec Biologics (搜索)' advanced platforms and scientific expertise to support the broader research ecosystem. This partnership strengthens our shared mission to accelerate the development of biotherapeutics (搜索) that address urgent and unmet medical needs."
Just-Evotec Biologics (搜索) operates as a first-to-industry biologics platform company that combines deep industry experience in data, protein, process, and manufacturing sciences with highly integrated and flexible capabilities. The company's focus centers on accelerating and expanding access to biotherapeutics (搜索) through scientific and technological innovation, breaking through the scientific and economic barriers associated with protein therapeutics development.
The grant represents a significant step forward in making advanced biotherapeutics (搜索) more accessible globally, particularly in regions where infectious diseases pose substantial public health challenges. By optimizing monoclonal antibodies (搜索) and other biologic modalities through AI-driven approaches, the initiative aims to reduce manufacturing costs while maintaining therapeutic efficacy and safety profiles.